$514 Million is the total value of Eagle Health Investments LP's 27 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 42.9% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
NTRA | Sell | NATERA INC | $43,577,315 | +33.1% | 784,894 | -3.7% | 8.48% | +12.3% |
ALNY | Sell | ALNYLAM PHARMACEUTICALS INC | $27,394,962 | -26.0% | 136,756 | -12.2% | 5.33% | -37.5% |
OM | Sell | OUTSET MED INC | $22,087,084 | -29.9% | 1,200,385 | -1.7% | 4.30% | -40.9% |
TNDM | Sell | TANDEM DIABETES CARE INC | $17,280,570 | -34.9% | 425,525 | -27.9% | 3.36% | -45.1% |
ARVN | Exit | ARVINAS INC | $0 | – | -23,000 | -100.0% | -0.18% | – |
TXG | Exit | 10X GENOMICS INC | $0 | – | -49,200 | -100.0% | -0.41% | – |
CTLT | Exit | CATALENT INC | $0 | – | -329,100 | -100.0% | -3.42% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-12
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
IQVIA HLDGS INC | 12 | Q3 2023 | 9.6% |
UNITED THERAPEUTICS CORP DEL | 12 | Q3 2023 | 8.7% |
ALNYLAM PHARMACEUTICALS INC | 12 | Q3 2023 | 8.5% |
NATERA INC | 12 | Q3 2023 | 8.5% |
ARGENX SE | 12 | Q3 2023 | 7.0% |
DEXCOM INC | 12 | Q3 2023 | 5.7% |
OUTSET MED INC | 12 | Q3 2023 | 7.3% |
AGIOS PHARMACEUTICALS INC | 12 | Q3 2023 | 7.2% |
ADAPTIVE BIOTECHNOLOGIES COR | 12 | Q3 2023 | 5.1% |
GUARDANT HEALTH INC | 12 | Q3 2023 | 3.8% |
View Eagle Health Investments LP's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-12 |
13F-HR | 2023-10-27 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-12 |
13F-HR | 2023-02-13 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-11 |
13F-HR | 2022-05-12 |
13F-HR | 2022-02-10 |
13F-HR | 2021-10-20 |
View Eagle Health Investments LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.